TELA Bio (TELA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TELA Stock Forecast

TELA Bio stock forecast is as follows: an average price target of $12.50 (represents a 315.28% upside from TELA’s last price of $3.01) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

TELA Price Target

The average price target for TELA Bio (TELA) is $12.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $8.00. This represents a potential 315.28% upside from TELA's last price of $3.01.

TELA Analyst Ratings

Buy

According to 2 Wall Street analysts, TELA Bio's rating consensus is 'Buy'. The analyst rating breakdown for TELA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

TELA Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 04, 2024	Frank Takkinen	Lake Street	-	-	217.46%	165.78%
Aug 13, 2024	Matt O'Brien	Piper Sandler	-	-	99.50%	165.78%
May 22, 2024	Kyle Rose	Canaccord Genuity	-	-	125.81%	365.12%
May 10, 2024	Matt O'Brien	Piper Sandler	-	-	73.01%	232.23%
Nov 10, 2022		JMP Securities	-	-	146.91%	564.45%
Nov 09, 2022	Matt O'Brien	Piper Sandler	-	-	130.77%	398.34%

Row per page

Go to

The latest TELA Bio stock forecast, released on Oct 04, 2024 by Frank Takkinen from Lake Street, set a price target of $8.00, which represents a 217.46% increase from the stock price at the time of the forecast ($2.52), and a 165.78% increase from TELA last price ($3.01).

TELA Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$8.00	$10.00
Last Closing Price	$3.01	$3.01	$3.01
Upside/Downside	-100.00%	165.78%	232.23%

In the current month, the average price target of TELA Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TELA Bio's last price of $3.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 04, 2024	Piper Sandler	Market Outperform	Market Outperform	Hold
Oct 04, 2024	Lake Street	Underperform	Underperform	Hold
Oct 04, 2024	Lake Street	Buy	Buy	Hold
Oct 04, 2024	Canaccord Genuity	Buy	Buy	Hold
Aug 13, 2024	Piper Sandler	Overweight	Overweight	Hold
May 22, 2024	Canaccord Genuity	Buy	Buy	Hold
May 10, 2024	Piper Sandler	Overweight	Overweight	Hold
Nov 09, 2022	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

TELA Bio's last stock rating was published by Piper Sandler on Oct 23, 2024. The company gave TELA a "Overweight" rating, the same as its previous rate.

TELA Bio Financial Forecast

TELA Bio Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$17.00M	$15.05M	$14.49M	$11.91M	$11.62M	$11.16M	$10.41M	$8.23M	$8.37M	$7.65M	$7.56M	$5.88M	$5.67M	$5.31M	$3.51M	$3.73M	$4.86M	$3.97M
Avg Forecast	$34.28M	$30.09M	$27.06M	$25.64M	$26.79M	$23.50M	$22.36M	$21.16M	$23.18M	$18.85M	$18.45M	$16.32M	$16.46M	$16.20M	$14.39M	$12.01M	$13.18M	$10.86M	$10.12M	$7.94M	$7.97M	$7.55M	$6.31M	$5.46M	$5.81M	$4.57M	$1.94M	$3.66M	$4.17M	$3.94M
High Forecast	$35.21M	$30.92M	$27.80M	$26.34M	$27.52M	$24.14M	$22.97M	$21.74M	$23.67M	$18.89M	$18.45M	$16.32M	$16.71M	$16.20M	$14.78M	$12.34M	$13.54M	$10.86M	$10.12M	$7.94M	$7.97M	$7.55M	$6.31M	$5.46M	$5.81M	$4.57M	$1.94M	$3.66M	$4.17M	$3.94M
Low Forecast	$33.65M	$29.54M	$26.56M	$25.17M	$26.29M	$23.07M	$21.95M	$20.77M	$22.68M	$18.80M	$18.45M	$16.32M	$16.21M	$16.20M	$14.13M	$11.79M	$12.94M	$10.86M	$10.12M	$7.94M	$7.97M	$7.55M	$6.31M	$5.46M	$5.81M	$4.57M	$1.94M	$3.66M	$4.17M	$3.94M
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.03%	0.93%	1.01%	0.99%	0.88%	1.03%	1.03%	1.04%	1.05%	1.01%	1.20%	1.08%	0.98%	1.16%	1.81%	1.02%	1.17%	1.01%

TELA Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.32M, with a low forecast of $16.32M, and a high forecast of $16.32M. TELA's average Quarter revenue forecast represents a -4.00% decrease compared to the company's last Quarter revenue of $17.00M (Dec 23).

TELA Bio EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-12.12M	$-9.62M	$-9.49M	$-10.78M	$-8.80M	$-9.48M	$-10.58M	$-9.80M	$-14.75M	$-7.22M	$-7.26M	$-7.11M	$-6.75M	$-6.67M	$-5.08M	$-6.21M	$-5.50M	$-3.62M
Avg Forecast	$-31.72M	$-27.85M	$-25.05M	$-23.73M	$-24.79M	$-21.75M	$-20.70M	$-19.59M	$-21.45M	$-17.44M	$-17.07M	$-15.10M	$-15.23M	$-15.00M	$-13.32M	$-11.12M	$-12.20M	$-10.17M	$-9.48M	$-5.00	$-7.46M	$-7.07M	$-5.91M	$-5.92M	$-5.44M	$-4.28M	$-1.81M	$-5.43M	$-3.91M	$-3.69M
High Forecast	$-31.14M	$-27.34M	$-24.58M	$-23.29M	$-24.33M	$-21.35M	$-20.32M	$-19.22M	$-20.99M	$-17.40M	$-17.07M	$-15.10M	$-15.00M	$-15.00M	$-13.07M	$-10.91M	$-11.98M	$-10.17M	$-9.48M	$-4.00	$-7.46M	$-7.07M	$-5.91M	$-4.74M	$-5.44M	$-4.28M	$-1.81M	$-4.35M	$-3.91M	$-3.69M
Low Forecast	$-32.59M	$-28.61M	$-25.73M	$-24.38M	$-25.47M	$-22.34M	$-21.26M	$-20.12M	$-21.91M	$-17.48M	$-17.07M	$-15.10M	$-15.46M	$-15.00M	$-13.68M	$-11.42M	$-12.53M	$-10.17M	$-9.48M	$-6.00	$-7.46M	$-7.07M	$-5.91M	$-7.11M	$-5.44M	$-4.28M	$-1.81M	$-6.52M	$-3.91M	$-3.69M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.80%	0.64%	0.71%	0.97%	0.72%	0.93%	1.12%	1959400.00%	1.98%	1.02%	1.23%	1.20%	1.24%	1.56%	2.80%	1.14%	1.41%	0.98%

undefined analysts predict TELA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TELA Bio's previous annual EBITDA (undefined) of $NaN.

TELA Bio Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-12.89M	$-10.96M	$-10.79M	$-14.05M	$-9.77M	$-11.94M	$-13.35M	$-11.88M	$-2.35M	$-8.27M	$-8.26M	$-8.14M	$-7.79M	$-7.70M	$-6.08M	$-7.22M	$-6.53M	$-4.67M
Avg Forecast	$-951.09K	$-1.22M	$-1.38M	$-1.90M	$-3.12M	$-4.06M	$-4.04M	$-4.90M	$-5.27M	$-10.00M	$-11.28M	$-12.07M	$-11.01M	$-11.88M	$-12.90M	$-13.52M	$-13.16M	$-14.72M	$-14.91M	$-5.00	$-12.86M	$-12.78M	$-12.69M	$-6.78M	$-11.85M	$-11.90M	$-14.61M	$-6.32M	$-14.67M	$-13.81M
High Forecast	$-928.31K	$-1.19M	$-1.35M	$-1.86M	$-3.05M	$-3.97M	$-3.94M	$-4.78M	$-3.66M	$-9.76M	$-11.01M	$-11.79M	$-10.51M	$-11.59M	$-12.59M	$-13.19M	$-12.85M	$-14.72M	$-14.91M	$-4.00	$-12.86M	$-12.78M	$-12.69M	$-5.42M	$-11.85M	$-11.90M	$-14.61M	$-5.05M	$-14.67M	$-13.81M
Low Forecast	$-984.80K	$-1.26M	$-1.43M	$-1.97M	$-3.23M	$-4.21M	$-4.18M	$-5.07M	$-6.64M	$-10.35M	$-11.68M	$-12.50M	$-11.26M	$-12.30M	$-13.36M	$-13.99M	$-13.63M	$-14.72M	$-14.91M	$-7.00	$-12.86M	$-12.78M	$-12.69M	$-8.14M	$-11.85M	$-11.90M	$-14.61M	$-7.58M	$-14.67M	$-13.81M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.17%	0.92%	0.84%	1.04%	0.74%	0.81%	0.90%	2376000.00%	0.18%	0.65%	0.65%	1.20%	0.66%	0.65%	0.42%	1.14%	0.45%	0.34%

TELA Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TELA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

TELA Bio SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$21.22M	$18.20M	$18.05M	$17.10M	$14.89M	$14.70M	$14.69M	$12.84M	$11.59M	$10.41M	$10.47M	$9.05M	$9.25M	$8.95M	$6.27M	$7.79M	$7.87M	$5.94M
Avg Forecast	$50.78M	$44.58M	$40.09M	$37.99M	$39.68M	$34.82M	$33.13M	$31.35M	$34.33M	$27.92M	$27.33M	$24.17M	$24.38M	$24.01M	$21.32M	$17.80M	$19.53M	$16.09M	$14.99M	$6.00	$11.80M	$11.19M	$9.35M	$8.09M	$8.60M	$6.77M	$2.87M	$5.43M	$6.18M	$5.83M
High Forecast	$52.16M	$45.80M	$41.18M	$39.02M	$40.76M	$35.77M	$34.03M	$32.20M	$35.07M	$27.98M	$27.33M	$24.17M	$24.75M	$24.01M	$21.90M	$18.28M	$20.06M	$16.09M	$14.99M	$8.00	$11.80M	$11.19M	$9.35M	$8.09M	$8.60M	$6.77M	$2.87M	$5.43M	$6.18M	$5.83M
Low Forecast	$49.84M	$43.76M	$39.35M	$37.29M	$38.95M	$34.17M	$32.52M	$30.77M	$33.60M	$27.85M	$27.33M	$24.17M	$24.02M	$24.01M	$20.93M	$17.47M	$19.17M	$16.09M	$14.99M	$5.00	$11.80M	$11.19M	$9.35M	$8.09M	$8.60M	$6.77M	$2.87M	$5.43M	$6.18M	$5.83M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.76%	0.85%	0.96%	0.76%	0.91%	0.98%	2139333.33%	0.98%	0.93%	1.12%	1.12%	1.07%	1.32%	2.19%	1.44%	1.27%	1.02%

TELA Bio's average Quarter SG&A projection for Mar 24 is $24.17M, based on 1 Wall Street analysts, with a range of $24.17M to $24.17M. The forecast indicates a 13.94% rise compared to TELA last annual SG&A of $21.22M (Dec 23).

TELA Bio EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.53	$-0.45	$-0.46	$-0.73	$-0.51	$-0.71	$-0.92	$-0.82	$-0.16	$-0.57	$-0.57	$-0.56	$-0.54	$-0.53	$-0.53	$-0.63	$-1.22	$-0.44
Avg Forecast	$-0.04	$-0.05	$-0.06	$-0.08	$-0.13	$-0.16	$-0.16	$-0.20	$-0.21	$-0.40	$-0.46	$-0.49	$-0.45	$-0.48	$-0.52	$-0.55	$-0.53	$-0.60	$-0.60	$-0.54	$-0.52	$-0.52	$-0.51	$-0.48	$-0.48	$-0.48	$-0.59	$-0.57	$-0.59	$-0.56
High Forecast	$-0.04	$-0.05	$-0.05	$-0.08	$-0.12	$-0.16	$-0.16	$-0.19	$-0.15	$-0.40	$-0.45	$-0.48	$-0.43	$-0.47	$-0.51	$-0.53	$-0.52	$-0.60	$-0.60	$-0.54	$-0.52	$-0.52	$-0.51	$-0.48	$-0.48	$-0.48	$-0.59	$-0.57	$-0.59	$-0.56
Low Forecast	$-0.04	$-0.05	$-0.06	$-0.08	$-0.13	$-0.17	$-0.17	$-0.21	$-0.27	$-0.42	$-0.47	$-0.51	$-0.46	$-0.50	$-0.54	$-0.57	$-0.55	$-0.60	$-0.60	$-0.54	$-0.52	$-0.52	$-0.51	$-0.48	$-0.48	$-0.48	$-0.59	$-0.57	$-0.59	$-0.56
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.19%	0.94%	0.88%	1.33%	0.96%	1.19%	1.52%	1.52%	0.31%	1.10%	1.11%	1.18%	1.12%	1.10%	0.89%	1.11%	2.05%	0.78%

According to undefined Wall Street analysts, TELA Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TELA previous annual EPS of $NaN (undefined).

TELA Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
TELA	TELA Bio	-	-	315.28%	Buy
DCTH	Delcath Systems	-	-	125.41%	Buy
SGHT	Sight Sciences	-	-	124.44%	Hold
LUNG	Pulmonx	-	-	75.70%	Buy
TMDX	TransMedics Group	-	-	66.69%	Buy
SIBN	SI-BONE	-	-	59.24%	Buy
RXST	RxSight	-	-	56.39%	Buy
KIDS	OrthoPediatrics	-	-	50.34%	Buy
NPCE	NeuroPace	-	-	32.78%	Buy
OFIX	Orthofix Medical	-	-	26.92%
FNA	Paragon 28	-	-	14.54%	Buy
CVRX	CVRx	-	-	9.97%	Buy
VREX	Varex Imaging	-	-	2.16%	Buy
CLPT	ClearPoint Neuro	-	-	1.35%	Buy
TCMD	Tactile Systems	-	-	-10.36%	Buy

TELA Forecast FAQ

Is TELA Bio a good buy?

Yes, according to 2 Wall Street analysts, TELA Bio (TELA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of TELA's total ratings.

What is TELA's price target?

TELA Bio (TELA) average price target is $12.5 with a range of $8 to $20, implying a 315.28% from its last price of $3.01. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will TELA Bio stock go up soon?

According to Wall Street analysts' prediction for TELA stock, the company can go up by 315.28% (from the last price of $3.01 to the average price target of $12.5), up by 564.45% based on the highest stock price target, and up by 165.78% based on the lowest stock price target.

Can TELA Bio stock reach $5?

TELA's average twelve months analyst stock price target of $12.5 supports the claim that TELA Bio can reach $5 in the near future.

What are TELA Bio's analysts' financial forecasts?

TELA Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $93.82M (high $96.37M, low $92.09M), average EBITDA is $-86.823M (high $-85.223M, low $-89.191M), average net income is $-16.126M (high $-15.74M, low $-16.698M), average SG&A $138.98M (high $142.77M, low $136.42M), and average EPS is $-0.653 (high $-0.637, low $-0.676). TELA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $117.08M (high $120.27M, low $114.92M), average EBITDA is $-108M (high $-106M, low $-111M), average net income is $-5.453M (high $-5.323M, low $-5.647M), average SG&A $173.44M (high $178.17M, low $170.24M), and average EPS is $-0.221 (high $-0.215, low $-0.229).

Did the TELA's actual financial results beat the analysts' financial forecasts?

Based on TELA Bio's last annual report (Dec 2023), the company's revenue was $58.45M, which missed the average analysts forecast of $59.07M by -1.04%. Apple's EBITDA was $-44.075M, missing the average prediction of $-54.667M by -19.38%. The company's net income was $-46.664M, missing the average estimation of $-49.302M by -5.35%. Apple's SG&A was $74.57M, missing the average forecast of $87.51M by -14.78%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-1.996 by -99.90%. In terms of the last quarterly report (Dec 2023), TELA Bio's revenue was $17M, beating the average analysts' forecast of $16.46M by 3.27%. The company's EBITDA was $-12.117M, missing the average prediction of $-15.233M by -20.45%. TELA Bio's net income was $-12.89M, beating the average estimation of $-11.009M by 17.08%. The company's SG&A was $21.22M, missing the average forecast of $24.38M by -12.99%. Lastly, the company's EPS was $-0.53, beating the average prediction of $-0.446 by 18.92%